Race in clinical trials in Sweden: How regulatory and medical standards in clinical research trump the post-racial discourse
- PMID: 37699725
- DOI: 10.1111/1467-9566.13709
Race in clinical trials in Sweden: How regulatory and medical standards in clinical research trump the post-racial discourse
Abstract
The post-racial discourse that permeates many Western European countries depicts society as having moved beyond race concepts and classifications. This article focuses on Sweden, a country that, in line with the post-racial thinking, declares race to be an offensive and unscientific concept. The article investigates what happens when this post-racial discourse meets clinical research standards that encourage, if not demand, the collection of data on patient race. Through an analysis of the reporting of patient race in 76 multinational trials with at least one study site in Sweden, and a review of the regulatory and medical standards and trial documents that direct the collection of patient race in trials, we show how race classification is kept intact in trials despite conflicting with post-racial norms and conventions. Notably, our findings diverge from the way racialisation is typically assumed to work in Sweden and related countries. We argue this is possible because the two incompatible understandings of race are 'distributed' (Mol, 2002, The body multiple: Ontology in medical practice, Duke University Press) among different social worlds. The distribution, we propose, is upheld through the paucity of major debate on why and how race classification should be carried out in clinical trials in Europe as this allows contradictions to remain unspoken.
Keywords: Europe; Sweden; clinical trials; ethnicity; post-racial; race; standardisation.
© 2023 The Authors. Sociology of Health & Illness published by John Wiley & Sons Ltd on behalf of Foundation for the Sociology of Health & Illness.
Similar articles
-
Is Our Science Representative? A Systematic Review of Racial and Ethnic Diversity in Orthopaedic Clinical Trials from 2000 to 2020.Clin Orthop Relat Res. 2022 May 1;480(5):848-858. doi: 10.1097/CORR.0000000000002050. Epub 2021 Dec 2. Clin Orthop Relat Res. 2022. PMID: 34855650 Free PMC article.
-
Diversity in clinical trials in Europe and the USA: a review of a pharmaceutical company's data collection, reporting, and interpretation of race and ethnicity.Ann Oncol. 2023 Dec;34(12):1194-1197. doi: 10.1016/j.annonc.2023.09.3107. Epub 2023 Sep 27. Ann Oncol. 2023. PMID: 37774795 No abstract available.
-
Reporting of Participant Race and Ethnicity in Published US Pediatric Clinical Trials From 2011 to 2020.JAMA Pediatr. 2022 May 1;176(5):e220142. doi: 10.1001/jamapediatrics.2022.0142. Epub 2022 May 2. JAMA Pediatr. 2022. PMID: 35311946 Free PMC article.
-
Race-based therapy for hypertension: possible benefits and potential pitfalls.Expert Rev Cardiovasc Ther. 2008 Nov;6(10):1357-66. doi: 10.1586/14779072.6.10.1357. Expert Rev Cardiovasc Ther. 2008. PMID: 19018689 Review.
-
Racial and Ethnic Disparities in Primary Open-Angle Glaucoma Clinical Trials: A Systematic Review and Meta-analysis.JAMA Netw Open. 2021 May 3;4(5):e218348. doi: 10.1001/jamanetworkopen.2021.8348. JAMA Netw Open. 2021. PMID: 34003274 Free PMC article.
Cited by
-
Racial and Ethnic Disparities in European Breast Cancer Clinical Trials.Cancers (Basel). 2024 Apr 29;16(9):1726. doi: 10.3390/cancers16091726. Cancers (Basel). 2024. PMID: 38730678 Free PMC article.
-
Racism against healthcare users in inpatient care: a scoping review.Int J Equity Health. 2024 May 2;23(1):89. doi: 10.1186/s12939-024-02156-w. Int J Equity Health. 2024. PMID: 38698455 Free PMC article.
-
Race and ethnicity matter! Moving Parkinson's risk research towards diversity and inclusiveness.NPJ Parkinsons Dis. 2025 Mar 7;11(1):45. doi: 10.1038/s41531-025-00891-7. NPJ Parkinsons Dis. 2025. PMID: 40050644 Free PMC article. Review.
-
Transnational adoptees in healthcare: barriers, resources, and needs.Front Public Health. 2024 Aug 22;12:1426489. doi: 10.3389/fpubh.2024.1426489. eCollection 2024. Front Public Health. 2024. PMID: 39238539 Free PMC article.
-
Race and Ethnicity in Heart Failure Trials: Time to Update Recommended Categories for Global Relevance.J Am Heart Assoc. 2025 Jun 17;14(12):e037810. doi: 10.1161/JAHA.124.037810. Epub 2025 Jun 11. J Am Heart Assoc. 2025. PMID: 40497494 Free PMC article.
References
REFERENCES
-
- Ahlberg, B. M., Hamed, S., Thapar-Björkert, S., & Bradby, H. (2019). Invisibility of racism in the global neoliberal era: Implications for researching racism in healthcare. Frontiers in Sociology, 4, 61. https://doi.org/10.3389/fsoc.2019.00061
-
- Astellas Pharma. (2007). SmPC: Advagraf prolonged-release hard capsules. https://www.ema.europa.eu/en/documents/product-information/advagraf-epar...
-
- AstraZeneca. (2019). Statistical analysis plan - Acute STroke or Transient IscHaemic Attack treated with TicAgreLor and ASA for PrEvention of Stroke and Death (THALES). https://clinicaltrials.gov/ct2/show/NCT03354429
-
- AstraZeneca. (2021). SmPC: Crestor 5mg film-coated tablets. https://www.medicines.org.uk/emc/product/6779/smpc#gref
-
- Balkenhol, M., & Schramm, K. (2019). Doing race in Europe: Contested pasts and contemporary practices. Social Anthropology, 27(4), 585-593. https://doi.org/10.1111/1469-8676.12721
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical